Interestingly, it has been recently reported that small EGFR inhibitors such as AG1478, erlotinib, gefitinib and lapatinib, as opposed to the EGFR monoclonal antibody cetuximab, also reduce erbB3 and erbB4 phosphorylation, and this inhibition correlates with their cellular activity in glioma cells [7]. Here, ERBB3 is linked to glioma.